Literature DB >> 27652317

Exercise: A new role for an old tool.

Manja Idorn1, Per Thor Straten2.   

Abstract

We recently demonstrated that voluntary exercise leads to an influx of immune cells in tumors and a greater than 60% reduction in tumor incidence and growth across several mouse models. Improved immunological control of tumor progression may have important clinical implications in the prevention and treatment of cancer in humans.

Entities:  

Keywords:  Exercise; NK cells; immune infiltration; tumor growth

Year:  2016        PMID： 27652317      PMCID： PMC4972115          DOI： 10.1080/23723556.2016.1163005

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

Authors:  Steven A Rosenberg; James C Yang; Richard M Sherry; Udai S Kammula; Marybeth S Hughes; Giao Q Phan; Deborah E Citrin; Nicholas P Restifo; Paul F Robbins; John R Wunderlich; Kathleen E Morton; Carolyn M Laurencot; Seth M Steinberg; Donald E White; Mark E Dudley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

2.  Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells.

Authors:  Austin B Bigley; Katayoun Rezvani; Claude Chew; Takuya Sekine; Mira Pistillo; Brian Crucian; Catherine M Bollard; Richard J Simpson
Journal:  Brain Behav Immun       Date:  2013-11-05       Impact factor: 7.217

Review 3.  The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

Authors:  Daniel Sanghoon Shin; Antoni Ribas
Journal:  Curr Opin Immunol       Date:  2015-01-23       Impact factor: 7.486

Review 4.  Effects of exercise on tumor physiology and metabolism.

Authors:  Line Pedersen; Jesper Frank Christensen; Pernille Hojman
Journal:  Cancer J       Date:  2015 Mar-Apr       Impact factor: 3.360

5.  Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Authors:  Antonella Sistigu; Takahiro Yamazaki; Erika Vacchelli; Kariman Chaba; David P Enot; Julien Adam; Ilio Vitale; Aicha Goubar; Elisa E Baracco; Catarina Remédios; Laetitia Fend; Dalil Hannani; Laetitia Aymeric; Yuting Ma; Mireia Niso-Santano; Oliver Kepp; Joachim L Schultze; Thomas Tüting; Filippo Belardelli; Laura Bracci; Valentina La Sorsa; Giovanna Ziccheddu; Paola Sestili; Francesca Urbani; Mauro Delorenzi; Magali Lacroix-Triki; Virginie Quidville; Rosa Conforti; Jean-Philippe Spano; Lajos Pusztai; Vichnou Poirier-Colame; Suzette Delaloge; Frederique Penault-Llorca; Sylvain Ladoire; Laurent Arnould; Joanna Cyrta; Marie-Charlotte Dessoliers; Alexander Eggermont; Marco E Bianchi; Mikael Pittet; Camilla Engblom; Christina Pfirschke; Xavier Préville; Gilles Uzè; Robert D Schreiber; Melvyn T Chow; Mark J Smyth; Enrico Proietti; Fabrice André; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2014-10-26       Impact factor: 53.440

6.  Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution.

Authors:  Line Pedersen; Manja Idorn; Gitte H Olofsson; Britt Lauenborg; Intawat Nookaew; Rasmus Hvass Hansen; Helle Hjorth Johannesen; Jürgen C Becker; Katrine S Pedersen; Christine Dethlefsen; Jens Nielsen; Julie Gehl; Bente K Pedersen; Per Thor Straten; Pernille Hojman
Journal:  Cell Metab       Date:  2016-02-16       Impact factor: 27.287

7.  Shaping of NK cell responses by the tumor microenvironment.

Authors:  Ana Stojanovic; Margareta P Correia; Adelheid Cerwenka
Journal:  Cancer Microenviron       Date:  2012-12-16

Review 8.  Mechanisms linking physical activity with cancer.

Authors:  Anne McTiernan
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

9.  Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.

Authors:  Rikke Andersen; Marco Donia; Eva Ellebaek; Troels Holz Borch; Per Kongsted; Trine Zeeberg Iversen; Lisbet Rosenkrantz Hölmich; Helle Westergren Hendel; Özcan Met; Mads Hald Andersen; Per Thor Straten; Inge Marie Svane
Journal:  Clin Cancer Res       Date:  2016-03-22       Impact factor: 12.531

10.  Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.

Authors:  Stefani Spranger; Holly K Koblish; Brendan Horton; Peggy A Scherle; Robert Newton; Thomas F Gajewski
Journal:  J Immunother Cancer       Date:  2014-02-18       Impact factor: 13.751
  10 in total
  2 in total

Review 1.  From NASH to HCC: current concepts and future challenges.

Authors:  Quentin M Anstee; Helen L Reeves; Elena Kotsiliti; Olivier Govaere; Mathias Heikenwalder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

2.  Exercise duRing Active Surveillance for prostatE cancer-the ERASE trial: a study protocol of a phase II randomised controlled trial.

Authors:  Dong-Woo Kang; Adrian S Fairey; Normand G Boulé; Catherine J Field; Kerry S Courneya
Journal:  BMJ Open       Date:  2019-07-04       Impact factor: 2.692
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.